17 November, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 23 October 2026 regarding the inspection conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen), a wholly owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, from 19 October 2026 to 22 October 2026, we hereby notify that the USFDA, vide its communication dated 17 November 2026, has classified the aforementioned inspection as No Action Indicated (NAI).

Please take the above information on record.

Yours faithfully,
For Cipla Limited

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.11.17 23:09:28 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani